EBMT-EHA CAR-T 2019 | Treating pediatric patients with hematological malignancies
Claudia Rössig, MD, of the University of Münster, Münster, Germany, talks about whether there are any differences when it comes to treating pediatric patients with CAR T-cell therapy compared with treating adult patients. Dr Rössig explains that there are actually no signifcantly unique challenges with treating this patient group, and the toxicities are similar as those for adult patients. Recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
